Daruwala Paul 4/A
4/A · Cidara Therapeutics, Inc. · Filed Jun 25, 2020
Insider Transaction Report
Form 4/AAmended
Daruwala Paul
Chief Medical Officer
Transactions
- Sale
Common Stock
2020-01-03$3.42/sh−940$3,215→ 52,592 total
Footnotes (2)
- [F1]This amendment is being filed to correct the number of shares sold which were underreported by 940 shares (i.e. a total of 3,280 shares were sold rather than 2,340) and to correct the end of period holdings to reduce such amount by 940 shares.
- [F2]Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 12/31/19. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.